AnaptysBio, Inc. $ANAB Shares Sold by DCF Advisers LLC

DCF Advisers LLC cut its position in AnaptysBio, Inc. (NASDAQ:ANAB) by 26.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 35,250 shares of the biotechnology company’s stock after selling 12,750 shares during the quarter. DCF Advisers LLC owned approximately 0.13% of AnaptysBio worth $1,709,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in ANAB. AQR Capital Management LLC boosted its position in shares of AnaptysBio by 153.3% in the 1st quarter. AQR Capital Management LLC now owns 30,011 shares of the biotechnology company’s stock valued at $558,000 after purchasing an additional 18,165 shares during the period. Creative Planning boosted its position in shares of AnaptysBio by 26.9% in the 2nd quarter. Creative Planning now owns 16,854 shares of the biotechnology company’s stock valued at $374,000 after purchasing an additional 3,571 shares during the period. JPMorgan Chase & Co. boosted its position in shares of AnaptysBio by 1,631.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 247,625 shares of the biotechnology company’s stock valued at $5,497,000 after purchasing an additional 233,325 shares during the period. Russell Investments Group Ltd. acquired a new stake in shares of AnaptysBio in the 2nd quarter valued at about $528,000. Finally, Arrowstreet Capital Limited Partnership acquired a new stake in shares of AnaptysBio in the 2nd quarter valued at about $3,348,000.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on ANAB. Barclays increased their price objective on AnaptysBio from $63.00 to $75.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 13th. Stifel Nicolaus increased their price objective on AnaptysBio from $56.00 to $85.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Zacks Research cut AnaptysBio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 2nd. Truist Financial raised AnaptysBio to a “hold” rating in a research report on Wednesday, March 25th. Finally, HC Wainwright began coverage on AnaptysBio in a research report on Wednesday. They set a “buy” rating and a $95.00 price objective for the company. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $81.82.

Insider Buying and Selling

In other news, Director John P. Schmid sold 20,645 shares of the stock in a transaction that occurred on Monday, March 30th. The stock was sold at an average price of $56.11, for a total transaction of $1,158,390.95. Following the completion of the transaction, the director directly owned 31,622 shares of the company’s stock, valued at approximately $1,774,310.42. This represents a 39.50% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Daniel Faga sold 17,679 shares of the stock in a transaction that occurred on Friday, March 27th. The stock was sold at an average price of $61.61, for a total value of $1,089,203.19. Following the transaction, the chief executive officer directly owned 495,965 shares of the company’s stock, valued at approximately $30,556,403.65. This trade represents a 3.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 33.50% of the company’s stock.

AnaptysBio Trading Up 0.9%

Shares of ANAB stock opened at $52.10 on Thursday. The company has a market cap of $1.52 billion, a price-to-earnings ratio of -48.24 and a beta of 0.72. The stock has a 50 day simple moving average of $60.38 and a 200-day simple moving average of $54.30. AnaptysBio, Inc. has a 12-month low of $11.40 and a 12-month high of $72.36.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Tuesday, May 12th. The biotechnology company reported ($1.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($1.20). The business had revenue of $25.56 million for the quarter, compared to analysts’ expectations of $18.86 million. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 11.53%. On average, equities analysts forecast that AnaptysBio, Inc. will post -0.93 earnings per share for the current fiscal year.

AnaptysBio declared that its Board of Directors has initiated a share repurchase program on Friday, March 27th that allows the company to buyback $100,000.00 billion in shares. This buyback authorization allows the biotechnology company to repurchase up to 5,352,316.2% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s management believes its stock is undervalued.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.